Sugemalimab|2256084-03-2|(舒格利单抗)-陌孚医药/Medlife

您当前的位置：

Sugemalimab (Synonyms: 舒格利单抗)

目录号: PL08936

CAS No. :2256084-03-2

商品编号	规格	价格	会员价
PL08936-1mg	1mg	¥13340.00	请登录
PL08936-5mg	5mg	询价	询价
PL08936-10mg	10mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Sugemalimab
中文别名	舒格利单抗
英文名称	Sugemalimab
英文别名	Sugemalimab
Cas No.	2256084-03-2
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Sugemalimab 是一种完整的人全长抗程序性死亡配体 1 (PD-L1) 免疫球蛋白 G4 (IgG4) 单克隆抗体 (mAb)。Sugemalimab 显示出抗癌活性，可用于非小细胞肺癌的研究。

生物活性

Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.

性状

Liquid

IC50 & Target[1][2]

PD-L1

体外研究(In Vitro)

Sugemalimab (CS1001) specifically binds to PD-L1, competitively blocks the binding of human PD-L1 with PD-1 and CD80, and effectively induces CD4+?T lymphocyte proliferation and enhances the production of interferon-γ and interleukin-2.
Sugemalimab employs IgG4 isotype and lacks antibody-dependent cellular mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Sugemalimab (CS1001) signifcantly inhibits tumor growth in the subcutaneous MC38-hPD-L1 murine colon carcinoma (murine MC38 cells expressing human PD-L1) in human PD-1 knock-in mouse model.
Sugemalimab not only enhances the cytotoxic T cell/regulatory T cell ratio, but also significantly upregulates M1 macrophage and down-regulated MDSC (myeloid-derived suppressor cells) population in D-1/PD-L1 dual knock-in mice implanted with MC38-hPD-L1 tumor. has not independently confirmed the accuracy of these methods. They are for reference only.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
[2]. Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80(16_Supplement): 3260-3260.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation